Hot Features
Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company. The company focuses on the development and commercialization of a new molecular synthetic tetrahydrocannabinol (THC) analog under investigation for the treatment of adult patients with anxiety and cognitiv... MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company. The company focuses on the development and commercialization of a new molecular synthetic tetrahydrocannabinol (THC) analog under investigation for the treatment of adult patients with anxiety and cognitive decline typically associated with early-stage dementia. It is developing MIRA1a, a synthetic cannabinoid analog to treat anxiety and chronic pain by targeting the cannabinoid type 1 and type 2 receptors. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Baltimore, Maryland. Mehr anzeigen
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.02 | -1.75438596491 | 1.14 | 1.31 | 1.06 | 309744 | 1.22683786 | CS |
| 4 | 0.1 | 9.80392156863 | 1.02 | 1.328 | 0.8 | 382695 | 1.15346539 | CS |
| 12 | -0.05 | -4.2735042735 | 1.17 | 1.5 | 0.8 | 324959 | 1.20056421 | CS |
| 26 | 0.04 | 3.7037037037 | 1.08 | 2.5591 | 0.8 | 906222 | 1.5480841 | CS |
| 52 | -0.03 | -2.60869565217 | 1.15 | 5.01 | 0.51 | 1920050 | 2.93182407 | CS |
| 156 | -5.88 | -84 | 7 | 7.9799 | 0.51 | 1314730 | 2.83987017 | CS |
| 260 | -5.88 | -84 | 7 | 7.9799 | 0.51 | 1314730 | 2.83987017 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Die zuletzt besuchten Aktien werden in diesem Feld angezeigt, so dass Sie leicht zu den Aktien zurückkehren können, die Sie zuvor angesehen haben.
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
